护心康片联合治疗冠心病稳定型心绞痛痰瘀互结证的临床观察

发布时间：2018-05-13 06:40

本文选题：护心康片 + 稳定型心绞痛　；参考：《湖南中医药大学》2016年硕士论文

【摘要】：目的:观察评价护心康片联合治疗冠心病稳定型心绞痛痰瘀互结证的临床疗效及安全性。方法:选取湖南省中医药大学第一附属医院稳定型心绞痛痰瘀互结证住院患者60例,采用西雅图生活量表评估研究对象生活质量,依据随机数字表法分为治疗组和对照组,每组30例。治疗前后填写临床观察表,对照组常规西医基础治疗,治疗组在相同西医基础治疗上加服护心康片,疗程为4周。治疗后记录并分析比较两组患者的心绞痛积分、硝酸甘油停减率、心电图疗效改善情况、中医证候改善和中医证候积分,及血脂变化水平、Duke评分和西雅图生活量表评分。结果:(1)治疗组和对照组均能改善患者临床疗效,治疗组总有效率为90.0%,对照组为76.7%,且治疗组改善临床疗效优于对照组,两组比较差异有统计学意义(P0.05);(2)治疗组和对照组均能改善患者心电图,治疗组总有效率为80.0%,对照组为63.3%,且治疗组改善心电图疗效优于对照组,两组比较差异有统计学意义(P0.05);(3)治疗组和对照组均能改善患者心绞痛,治疗组总有效率为86.7%,对照组为66.7%,且治疗组改善心绞痛疗效优于对照组,两组比较差异有统计学意义(P0.05);(4)治疗组和对照组均能改善患者硝酸甘油停减情况,治疗组总有效率为90.0%,对照组为76.7%,且治疗组改善硝酸甘油停减情况优于对照组,两组比较差异有统计学意义(P0.05);(5)治疗组和对照组均能改善患者中医证候,治疗组总有效率为90.0%,对照组为73.3%,且治疗组改善中医证候优于对照组,两组比较差异有统计学意义(P0.05);(6)治疗组和对照组均能调节患者血脂水平,治疗前后比较差异有统计学意义(P0.05),治疗后两组血脂水平比较,治疗组明显优于对照组,两组比较差异有统计学意义(P0.05);(7)治疗组和对照组均能改善患者Duke评分及西雅图生活量表评分,治疗后两组患者的Duke评分及西雅图生活量表评分均有改观,治疗组改善效果优于对照组,两组比较差异有统计学意义(P0.05);(8)安全性方面:治疗前后两组患者的血常规、电解质及肝肾功能检测结果均未出现明显变化,且均未出现严重的不良反应,两组组内和组间比较均无统计学意义(P0.05),因此联合护心康片与基础西医治疗同样具有良好的安全性。结论:护心康片联合治疗冠心病稳定型心绞痛痰瘀互结证疗效较单用基础西药治疗优势明显,并且能更有效改善患者血脂代谢功能,提高患者的Duke评分和生活质量。
[Abstract]:Objective: to evaluate the efficacy and safety of Huxinkang tablet in treating stable angina pectoris with phlegm and blood stasis syndrome. Methods: sixty patients with stable angina pectoris and phlegm and blood stasis syndrome were selected from the first affiliated Hospital of Hunan University of traditional Chinese Medicine. The quality of life was evaluated by Seattle Life scale. The patients were randomly divided into treatment group and control group. There were 30 cases in each group. Before and after treatment, the clinical observation form was filled out, the control group was treated with routine western medicine, the treatment group was treated with Huxinkang tablet on the same basic western medicine treatment, the course of treatment was 4 weeks. After treatment, the angina pectoris score, the stopping rate of nitroglycerin, the improvement of electrocardiogram, the improvement of TCM syndromes, the score of TCM syndromes, the Duke score of blood lipid change and the score of Seattle Life scale were recorded and compared between the two groups. Results both the treatment group and the control group could improve the clinical efficacy. The total effective rate of the treatment group was 90.0 and that of the control group was 76.70.The improvement of the clinical efficacy of the treatment group was better than that of the control group. The electrocardiogram was improved in the treatment group and the control group. The total effective rate was 80.0 in the treatment group and 63.3 in the control group, and the effect of improving ECG in the treatment group was better than that in the control group. The total effective rate of treatment group was 86.7, and that of control group was 66.7.The curative effect of treatment group on angina pectoris was better than that of control group. The difference between the two groups was statistically significant (P 0.05). Both the treatment group and the control group could improve the total effective rate of nitroglycerin. The total effective rate of the treatment group was 90.0 and that of the control group was 76.7.The effect of the treatment group was better than that of the control group, and the improvement of the treatment group was better than that of the control group. The difference between the two groups was statistically significant (P 0.05) the treatment group and the control group could improve the TCM syndromes of the patients. The total effective rate of the treatment group was 90.0 and the control group was 73.3%, and the treatment group improved the TCM syndrome better than the control group. The difference between the two groups was statistically significant (P 0.05) treatment group and control group were able to regulate the level of blood lipid, and the difference before and after treatment was statistically significant (P 0.05). After treatment, the treatment group was significantly better than the control group. The difference between the two groups was statistically significant (P 0.05). Both the treatment group and the control group could improve the Duke score and the Seattle Life scale score. After the treatment, the Duke score and the Seattle Life scale score of the two groups were improved. The improvement effect of the treatment group was better than that of the control group, and the difference between the two groups was statistically significant (P 0.05). The results of blood routine, electrolytes and liver and kidney function of the two groups were not significantly changed before and after treatment. There were no serious adverse reactions in both groups and there was no significant difference between the two groups. Therefore, the combination of Huxinkang tablets and basic western medicine treatment had good safety. Conclusion: the therapeutic effect of Huxinkang tablet in treating stable angina pectoris with phlegm and blood stasis syndrome is more effective than that of western medicine alone, and it can improve the blood lipid metabolism function and improve the Duke score and quality of life of the patients.
【学位授予单位】：湖南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【参考文献】